Clinical trial
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
NCT00048360 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00048360 |
|---|---|
| Title | Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults |
| Official title | An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder |
| Intervention type | Drug |
| Interventions | Extended-release bupropion hydrochloride |
| Enrollment | 162 |
| Start date | Oct 1, 2002 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Oct 31, 2002 |
| Last update posted | Feb 12, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: